Redox dysregulation originating from metabolic alterations and dependence on mitogenic and survival signaling through reactive oxygen species represents a specific vulnerability of malignant cells that can be selectively targeted by redox chemotherapeutics. This review will present an update on drug discovery, target identification, and mechanisms of action of experimental redox chemotherapeutics with a focus on pro- and antioxidant redox modulators now in advanced phases of preclinal and clinical development. Recent research indicates that numerous oncogenes and tumor suppressor genes exert their functions in part through redox mechanisms amenable to pharmacological intervention by redox chemotherapeutics. The pleiotropic action of many redox chemotherapeutics that involves simultaneous modulation of multiple redox sensitive targets can overcome cancer cell drug resistance originating from redundancy of oncogenic signaling and rapid mutation. Moreover, some redox chemotherapeutics may function according to the concept of synthetic lethality (i.e., drug cytotoxicity is confined to cancer cells that display loss of function mutations in tumor suppressor genes or upregulation of oncogene expression). The impressive number of ongoing clinical trials that examine therapeutic performance of novel redox drugs in cancer patients demonstrates that redox chemotherapy has made the crucial transition from bench to bedside. Antioxid. Redox Signal. 11, 3013–3069.
AdachiM, SakamotoH, KawamuraR, WangW, ImaiK, ShinomuraY. Nonsteroidal anti-inflammatory drugs and oxidative stress in cancer cells. Histol Histopathol, 22:437–442. 2007.
2.
Adam–ViziV, ChinopoulosC. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci, 27:639–645. 2006.
3.
AdamsBK, CaiJ, ArmstrongJ, HeroldM, LuYJ, SunA, SnyderJP, LiottaDC, JonesDP, ShojiM. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs, 16:263–275. 2005.
4.
AhmadIM, Aykin-BurnsN, SimJE, WalshSA, HigashikuboR, BuettnerGR, VenkataramanS, MackeyMA, FlanaganSW, OberleyLW, SpitzDR. Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem, 280:4254–4263. 2005.
5.
AlexandreJ, BatteuxF, NiccoC, ChereauC, LaurentA, GuillevinL, WeillB, GoldwasserF. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer, 119:41–48. 2006.
6.
AlexandreJ, HuY, LuW, PelicanoH, HuangP. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res, 67:3512–3517. 2007.
7.
AlexandreJ, NiccoC, ChereauC, LaurentA, WeillB, GoldwasserF, BatteuxF. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst, 98:236–244. 2006.
AmatoRJ, JacJ, Hernandez–McClainJ. Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results. Clin Genitourin Cancer, 6:73–78. 2008.
10.
AntosiewiczJ, Herman–AntosiewiczA, MarynowskiSW, SinghSV. c-Jun NH(2)-terminal kinase signaling axis regulates diallyl trisulfide-induced generation of reactive oxygen species and cell cycle arrest in human prostate cancer cells. Cancer Res, 66:5379–5386. 2006.
11.
AntosiewiczJ, ZiolkowskiW, KarS, PowolnyAA, SinghSV. Role of reactive oxygen intermediates in cellular responses to dietary cancer chemopreventive agents. Planta Med, 74:1570–1579. 2008.
12.
AsayamaS, KasugaiN, KubotaS, NagaokaS, KawakamiH. Superoxide dismutase as a target enzyme for Fe-porphyrin-induced cell death. J Inorg Biochem, 101:261–266. 2007.
13.
AsgariMM, MarutiSS, WhiteE. A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. J Natl Cancer Inst, 100:967–971. 2008.
14.
AsherG, DymO, TsvetkovP, AdlerJ, ShaulY. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol. Biochemistry, 45:6372–6378. 2006.
15.
Aykin–BurnsN, AhmadIM, ZhuY, OberleyLW, SpitzDR. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J, 418:29–37. 2009.
16.
AzadMB, ChenY, GibsonSB. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal, 11:777–790. 2009.
17.
BaelTE, PetersonBL, GollobJA. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res, 18:147–151. 2008.
18.
BahlisNJ, McCafferty–GradJ, Jordan–McMurryI, NeilJ, ReisI, Kharfan–DabajaM, EckmanJ, GoodmanM, FernandezHF, BoiseLH, LeeKP. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res, 8:3658–3668. 2002.
19.
BakerAF, DragovichT, TateWR, RamanathanRK, RoeD, HsuCH, KirkpatrickDL, PowisG. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med, 147:83–90. 2006.
20.
BakerAF, KohMY, WilliamsRR, JamesB, WangH, TateWR, GallegosA, Von HoffDD, HanH, PowisG. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas, 36:178–186. 2008.
21.
BakerAF, LandowskiT, DorrR, TateWR, GardJM, TavennerBE, DragovichT, CoonA, PowisG. The antitumor agent imexon activates antioxidant gene expression: Evidence for an oxidative stress response. Clin Cancer Res, 13:3388–3394. 2007.
22.
BarnettKT, FokumFD, MalafaMP. Vitamin E succinate inhibits colon cancer liver metastases. J Surg Res, 106:292–298. 2002.
23.
BeerheideW, SimMM, TanYJ, BernardHU, TingAE. Inactivation of the human papillomavirus-16 E6 oncoprotein by organic disulfides. Bioorg Med Chem, 8:2549–2560. 2000.
24.
BegleiterA, LeithMK, PatelD, HasinoffBB. Role of NADPH cytochrome P450 reductase in activation of RH1. Cancer Chemother Pharmacol, 60:713–723. 2007.
25.
BenllochM, MenaS, FerrerP, ObradorE, AsensiM, PellicerJA, CarreteroJ, OrtegaA, EstrelaJM. Bcl-2 and Mn-SOD antisense oligodeoxynucleotides and a glutamine-enriched diet facilitate elimination of highly resistant B16 melanoma cells by tumor necrosis factor-alpha and chemotherapy. J Biol Chem, 281:69–79. 2006.
26.
BensaadK, TsurutaA, SelakMA, VidalMN, NakanoK, BartronsR, GottliebE, VousdenKH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 126:107–120. 2006.
27.
BerensonJR, MatousJ, SwiftRA, MapesR, MorrisonB, YehHS. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res, 13:1762–1768. 2007.
28.
BergerTG, DieckmannD, EfferthT, SchultzES, FunkJO, BaurA, SchulerG. Artesunate in the treatment of metastatic uveal melanoma—First experiences. Oncol Rep, 14:1599–1603. 2005.
29.
BerkenblitA, EderJPJr., RyanDP, SeidenMV, TatsutaN, ShermanML, DahlTA, DezubeBJ, SupkoJG. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res, 13:584–590. 2007.
30.
BerndtssonM, HaggM, PanaretakisT, HavelkaAM, ShoshanMC, LinderS. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer, 120:175–180. 2007.
31.
BernhardtPV, WilsonGJ, SharpePC, KalinowskiDS, RichardsonDR. Tuning the antiproliferative activity of biologically active iron chelators: Characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands. J Biol Inorg Chem, 13:107–119. 2008.
32.
BerryJM, BradshawTD, FichtnerI, RenR, SchwalbeCH, WellsG, ChewEH, StevensMF, WestwellAD. Quinols as novel therapeutic agents. 2.(1) 4-(1-arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents. J Med Chem, 48:639–644. 2005.
33.
BhagavathulaN, NerusuKC, HanoshA, AslamMN, SundbergTB, OpipariAWJr., JohnsonK, KangS, GlickGD, VaraniJ. 7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalen-2-ylmethyl)-4,5-dihydr o-1H-benzo[b][1,4]diazepin-2(3H)-one (Bz-423), a benzodiazepine, suppresses keratinocyte proliferation and has antipsoriatic activity in the human skin-severe, combined immunodeficient mouse transplant model. J Pharmacol Exp Ther, 324:938–947. 2008.
34.
BlanchetotC, BoonstraJ. The ROS-NOX connection in cancer and angiogenesis. Crit Rev Eukaryot Gene Expr, 18:35–45. 2008.
35.
BlanderG, de OliveiraRM, ConboyCM, HaigisM, GuarenteL. Superoxide dismutase 1 knock-down induces senescence in human fibroblasts. J Biol Chem, 278:38966–38969. 2003.
36.
BoivinB, ZhangS, ArbiserJL, ZhangZY, TonksNK. A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells. Proc Natl Acad Sci USA, 105:9959–9964. 2008.
37.
BonnetS, ArcherSL, Allalunis–TurnerJ, HaromyA, BeaulieuC, ThompsonR, LeeCT, LopaschukGD, PuttaguntaL, BonnetS, HarryG, HashimotoK, PorterCJ, AndradeMA, ThebaudB, MichelakisED. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell, 11:37–51. 2007.
38.
BradshawTD, MatthewsCS, CooksonJ, ChewEH, ShahM, BaileyK, MonksA, HarrisE, WestwellAD, WellsG, LaughtonCA, StevensMF. Elucidation of thioredoxin as a molecular target for antitumor quinols. Cancer Res, 65:3911–3919. 2005.
39.
BrarSS, GriggC, WilsonKS, HolderWDJr., DreauD, AustinC, FosterM, GhioAJ, WhortonAR, StowellGW, WhittallLB, WhittleRR, WhiteDP, KennedyTP. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther, 3:1049–1060. 2004.
BrownDP, Chin–SinexH, NieB, MendoncaMS, WangM. Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer. Cancer Chemother Pharmacol, 63:723–730. 2009.
42.
BrownJM. Tumor hypoxia in cancer therapy. Methods Enzymol, 435:297–321. 2007.
43.
BrownKK, ErikssonSE, ArnerES, HamptonMB. Mitochondrial peroxiredoxin 3 is rapidly oxidized in cells treated with isothiocyanates. Free Radic Biol Med, 45:494–502. 2008.
44.
BuerkleA, WeberWA. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev, 27:545–554. 2008.
45.
BurkittMJ, BishopHS, MilneL, TsangSY, ProvanGJ, NobelCS, OrreniusS, SlaterAF. Dithiocarbamate toxicity toward thymocytes involves their copper-catalyzed conversion to thiuram disulfides, which oxidize glutathione in a redox cycle without the release of reactive oxygen species. Arch Biochem Biophys, 353:73–84. 1998.
46.
BushJA, CheungKJJr., LiG. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res, 271:305–314. 2001.
47.
CabelloCM, BairWB3rd, LamoreSD, LeyS, BauseAS, AzimianS, WondrakGT. The cinnamon-derived Michael acceptor cinnamic aldehyde impairs melanoma cell proliferation, invasiveness, and tumor growth. Free Radic Biol Med, 46:220–231. 2009.
48.
CabelloCM, BairWB3rd, WondrakGT. Experimental therapeutics: Targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs, 8:1022–1037. 2007.
CampER, SummyJ, BauerTW, LiuW, GallickGE, EllisLM. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res, 11:397–405. 2005.
51.
CanoCE, GommeauxJ, PietriS, CulcasiM, GarciaS, SeuxM, BarelierS, VasseurS, SpotoRP, PebusqueMJ, DusettiNJ, IovannaJL, CarrierA. Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Cancer Res, 69:219–226. 2009.
52.
CasiniA, ScozzafavaA, SupuranCT. Cysteine-modifying agents: a possible approach for effective anticancer and antiviral drugs. Environ Health Perspect, 110:801–806. 2002.
53.
CenD, BraytonD, ShahandehB, MeyskensFLJr., FarmerPJ. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem, 47:6914–6920. 2004.
54.
ChanK, PoonR, O'BrienPJ. Application of structure-activity relationships to investigate the molecular mechanisms of hepatocyte toxicity and electrophilic reactivity of alpha, beta-unsaturated aldehydes. J Appl Toxicol, 28:1027–1039. 2008.
55.
ChangHS, BaeSM, KimYW, KwakSY, MinHJ, BaeIJ, LeeYJ, ShinJC, KimCK, AhnWS. Comparison of diarsenic oxide and tetraarsenic oxide on anticancer effects: Relation to the apoptosis molecular pathway. Int J Oncol, 30:1129–1135. 2007.
56.
ChangJ, VoorheesP, KolesarJ, AhujaH, SanchezF, RodriguezG, KimK, WerndliJ, BaileyH, KahlB. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: A Wisconsin Oncology Network study. Hematol Oncol, 27:11–16. 2009.
57.
ChatterjiT, GatesKS. DNA cleavage by 7-methylbenzopentathiepin: a simple analog of the antitumor antibiotic varacin. Bioorg Med Chem Lett, 8:535–538. 1998.
58.
ChatterjiT, KeerthiK, GatesKS. Generation of reactive oxygen species by a persulfide (BnSSH)Bioorg Med Chem Lett, 15:3921–3924. 2005.
59.
ChatterjiT, KizilM, KeerthiK, ChowdhuryG, PospisilT, GatesKS. Small molecules that mimic the thiol-triggered alkylating properties seen in the natural product leinamycin. J Am Chem Soc, 125:4996–4997. 2003.
60.
ChenD, CuiQC, YangH, DouQP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res, 66:10425–10433. 2006.
ChenQ, EspeyMG, KrishnaMC, MitchellJB, CorpeCP, BuettnerGR, ShacterE, LevineM. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA, 102:13604–13609. 2005.
63.
ChenQ, EspeyMG, SunAY, LeeJH, KrishnaMC, ShacterE, ChoykePL, PooputC, KirkKL, BuettnerGR, LevineM. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA, 104:8749–8754. 2007.
64.
ChenQ, EspeyMG, SunAY, PooputC, KirkKL, KrishnaMC, KhoshDB, DriskoJ, LevineM. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA, 105:11105–11109. 2008.
65.
ChenY, JungsuwadeeP, VoreM, ButterfieldDA, St ClairDK. Collateral damage in cancer chemotherapy: Oxidative stress in nontargeted tissues. Mol Interv, 7:147–156. 2007.
66.
ChenY, McMillan–WardE, KongJ, IsraelsSJ, GibsonSB. Mitochondrial electron-transport-chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species. J Cell Sci, 120:4155–4166. 2007.
67.
ChewEH, LuJ, BradshawTD, HolmgrenA. Thioredoxin reductase inhibition by antitumor quinols: A quinol pharmacophore effect correlating to antiproliferative activity. FASEB J, 22:2072–2083. 2008.
68.
ChoiHS, ShimJS, KimJA, KangSW, KwonHJ. Discovery of gliotoxin as a new small molecule targeting thioredoxin redox system. Biochem Biophys Res Commun, 359:523–528. 2007.
69.
ChowMS, LiuLV, SolomonEI. Further insights into the mechanism of the reaction of activated bleomycin with DNA. Proc Natl Acad Sci USA, 105:13241–13245. 2008.
70.
ChuF, O'BrianCA. PKC sulfhydryl targeting by disulfiram produces divergent isozymic regulatory responses that accord with the cancer preventive activity of the thiuram disulfide. Antioxid Redox Signal, 7:855–862. 2005.
71.
ClarkeJD, DashwoodRH, HoE. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett, 269:291–304. 2008.
72.
ClarkeR, LiuMC, BoukerKB, GuZ, LeeRY, ZhuY, SkaarTC, GomezB, O'BrienK, WangY, Hilakivi–ClarkeLA. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene, 22:7316–7339. 2003.
73.
CullenJJ, HinkhouseMM, GradyM, GautAW, LiuJ, ZhangYP, WeydertCJ, DomannFE, OberleyLW. Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cancer Res, 63:5513–5520. 2003.
74.
DansonS, WardTH, ButlerJ, RansonM. DT-diaphorase: A target for new anticancer drugs. Cancer Treat Rev, 30:437–449. 2004.
75.
DasA, BanikNL, RaySK. Garlic compounds generate reactive oxygen species leading to activation of stress kinases and cysteine proteases for apoptosis in human glioblastoma T98G and U87MG cells. Cancer, 110:1083–1095. 2007.
76.
DavisWJr., RonaiZ, TewKD. Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp Ther, 296:1–6. 2001.
77.
DayBJ. Catalase and glutathione peroxidase mimics. Biochem Pharmacol, 77:285–296. 2009.
78.
DehnDL, SiegelD, ZafarKS, ReiganP, SwannE, MoodyCJ, RossD. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. Mol Cancer Ther, 5:1702–1709. 2006.
79.
Dell'EvaR, PfefferU, VeneR, AnfossoL, ForlaniA, AlbiniA, EfferthT. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol, 68:2359–2366. 2004.
80.
DhillonN, AggarwalBB, NewmanRA, WolffRA, KunnumakkaraAB, AbbruzzeseJL, NgCS, BadmaevV, KurzrockR. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res, 14:4491–4499. 2008.
DisbrowGL, BaegeAC, KierpiecKA, YuanH, CentenoJA, ThibodeauxCA, HartmannD, SchlegelR. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res, 65:10854–10861. 2005.
83.
DoctrowSR, HuffmanK, MarcusCB, ToccoG, MalfroyE, AdinolfiCA, KrukH, BakerK, LazarowychN, MascarenhasJ, MalfroyB. Salen-manganese complexes as catalytic scavengers of hydrogen peroxide and cytoprotective agents: structure-activity relationship studies. J Med Chem, 45:4549–4558. 2002.
84.
DoiK, AkaikeT, FujiiS, TanakaS, IkebeN, BeppuT, ShibaharaS, OgawaM, MaedaH. Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br J Cancer, 80:1945–1954. 1999.
85.
DolmaS, LessnickSL, HahnWC, StockwellBR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell, 3:285–296. 2003.
86.
DominiciS, ValentiniM, MaellaroE, Del BelloB, PaolicchiA, LorenziniE, TongianiR, ComportiM, PompellaA. Redox modulation of cell surface protein thiols in U937 lymphoma cells: The role of gamma-glutamyl transpeptidase-dependent H2O2 production and S-thiolation. Free Radic Biol Med, 27:623–635. 1999.
87.
DonateF, JuarezJC, BurnettME, ManuiaMM, GuanX, ShawDE, SmithEL, TimucinC, BraunsteinMJ, BatumanOA, MazarAP. Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224)Br J Cancer, 98:776–783. 2008.
DragovichT, GordonM, MendelsonD, WongL, ModianoM, ChowHH, SamulitisB, O'DayS, GrenierK, HershE, DorrR. Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol, 25:1779–1784. 2007.
90.
DuJ, DanielsDH, AsburyC, VenkataramanS, LiuJ, SpitzDR, OberleyLW, CullenJJ. Mitochondrial production of reactive oxygen species mediate dicumarol-induced cytotoxicity in cancer cells. J Biol Chem, 281:37416–37426. 2006.
91.
DurandRE, OlivePL. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Investig, 5:213–219. 1997.
92.
DvorakovaK, PayneCM, TomeME, BriehlMM, McClureT, DorrRT. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol, 60:749–758. 2000.
93.
DvorakovaK, WaltmireCN, PayneCM, TomeME, BriehlMM, DorrRT. Induction of mitochondrial changes in myeloma cells by imexon. Blood, 97:3544–3551. 2001.
94.
EfferthT. Mechanistic perspectives for 1,2,4-trioxanes in anticancer therapy. Drug Resist Updat, 8:85–97. 2005.
95.
EfferthT. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets, 7:407–421. 2006.
96.
EfferthT. Willmar Schwabe Award 2006: Antiplasmodial and antitumor activity of artemisinin—From bench to bedside. Planta Med, 73:299–309. 2007.
97.
EfferthT, BriehlMM, TomeME. Role of antioxidant genes for the activity of artesunate against tumor cells. Int J Oncol, 23:1231–1235. 2003.
98.
EvensAM, BalasubramanianL, GordonLI. Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies. Curr Treat Options Oncol, 6:289–296. 2005.
99.
FangJ, LuJ, HolmgrenA. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem, 280:25284–25290. 2005.
100.
FangJ, SawaT, AkaikeT, AkutaT, SahooSK, KhaledG, HamadaA, MaedaH. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res, 63:3567–3574. 2003.
101.
FangJ, SawaT, AkaikeT, GreishK, MaedaH. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer, 109:1–8. 2004.
102.
FangJS, GilliesRD, GatenbyRA. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol, 18:330–337. 2008.
103.
FavierJ, LapointeS, MalibaR, SiroisMG. HIF2 alpha reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma. BMC Cancer, 7:139. 2007.
104.
FilomeniG, AquilanoK, CivitarealeP, RotilioG, CirioloMR. Activation of c-Jun-N-terminal kinase is required for apoptosis triggered by glutathione disulfide in neuroblastoma cells. Free Radic Biol Med, 39:345–354. 2005.
105.
FilomeniG, AquilanoK, RotilioG, CirioloMR. Reactive oxygen species-dependent c-Jun NH2-terminal kinase/c-Jun signaling cascade mediates neuroblastoma cell death induced by diallyl disulfide. Cancer Res, 63:5940–5949. 2003.
106.
FilomeniG, RotilioG, CirioloMR. Glutathione disulfide induces apoptosis in U937 cells by a redox-mediated p38 MAP kinase pathway. FASEB J, 17:64–66. 2003.
107.
FilomeniG, TurellaP, DupuisML, ForiniO, CirioloMR, CianfrigliaM, PezzolaS, FedericiG, CaccuriAM. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer. Mol Cancer Ther, 7:371–379. 2008.
108.
FinchJS, TomeME, KweiKA, BowdenGT. Catalase reverses tumorigenicity in a malignant cell line by an epidermal growth factor receptor pathway. Free Radic Biol Med, 40:863–875. 2006.
FishelML, HeY, ReedAM, Chin–SinexH, HutchinsGD, MendoncaMS, KelleyMR. Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair (Amst), 7:177–186. 2008.
111.
FojoT. Commentary: Novel therapies for cancer: Why dirty might be better. Oncologist, 13:277–283. 2008.
112.
FoldiM, StickelerE, BauL, KretzO, WatermannD, GitschG, KayserG, Zur HausenA, CoyJF. Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep, 17:841–845. 2007.
113.
FrederiksenLJ, SullivanR, MaxwellLR, Macdonald–GoodfellowSK, AdamsMA, BennettBM, SiemensDR, GrahamCH. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res, 13:2199–2206. 2007.
114.
FribleyA, ZengQ, WangCY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol, 24:9695–9704. 2004.
115.
FriedL, ArbiserJL. The reactive oxygen-driven tumor: Relevance to melanoma. Pigment Cell Melanoma Res, 21:117–122. 2008.
116.
FrohlichDA, McCabeMT, ArnoldRS, DayML. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene, 27:4353–4362. 2008.
117.
FruehaufJP, MeyskensFLJr.Reactive oxygen species: A breath of life or death?Clin Cancer Res, 13:789–794. 2007.
118.
FruehaufJP, TrappV. Reactive oxygen species: An Achilles' heel of melanoma?Expert Rev Anticancer Ther, 8:1751–1757. 2008.
119.
FruehaufJP, ZonisS, al–BassamM, KyshtoobayevaA, DasguptaC, MilovanovicT, ParkerRJ, BuzaidAC. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase. Pigment Cell Res, 10:236–249. 1997.
FukuyoY, InoueM, NakajimaT, HigashikuboR, HorikoshiNT, HuntC, UshevaA, FreemanML, HorikoshiN. Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives. Cancer Res, 68:6324–6330. 2008.
122.
GallegosA, GasdaskaJR, TaylorCW, Paine–MurrietaGD, GoodmanD, GasdaskaPY, BerggrenM, BriehlMM, PowisG. Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res, 56:5765–5770. 1996.
123.
Garcia–PineresAJ, CastroV, MoraG, SchmidtTJ, StrunckE, PahlHL, MerfortI. Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem, 276:39713–39720. 2001.
124.
GarutiL, RobertiM, PizziraniD. Synthetic small molecule Cdc25 phosphatases inhibitors. Curr Med Chem, 15:573–580. 2008.
125.
GatenbyRA, GilliesRJ. Glycolysis in cancer: A potential target for therapy. Int J Biochem Cell Biol, 39:1358–1366. 2007.
126.
GeminA, SweetS, PrestonTJ, SinghG. Regulation of the cell cycle in response to inhibition of mitochondrial generated energy. Biochem Biophys Res Commun, 332:1122–1132. 2005.
127.
GilesGI. The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des, 12:4427–4443. 2006.
128.
GilesNM, GutowskiNJ, GilesGI, JacobC. Redox catalysts as sensitisers towards oxidative stress. FEBS Lett, 535:179–182. 2003.
129.
GiusD, SpitzDR. Redox signaling in cancer biology. Antioxid Redox Signal, 8:1249–1252. 2006.
130.
GongX, KoleL, IskanderK, JaiswalAK. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res, 67:5380–5388. 2007.
131.
GongY, SohnH, XueL, FirestoneGL, BjeldanesLF. 3,3′-Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Res, 66:4880–4887. 2006.
132.
GoplenD, WangJ, EngerPO, TysnesBB, TerzisAJ, LaerumOD, BjerkvigR. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res, 66:9895–9902. 2006.
133.
GottliebE, TomlinsonIP. Mitochondrial tumour suppressors: A genetic and biochemical update. Nat Rev Cancer, 5:857–866. 2005.
GreerA. On the origin of cytotoxicity of the natural product varacin. A novel example of a pentathiepin reaction that provides evidence for a triatomic sulfur intermediate. J Am Chem Soc, 123:10379–10386. 2001.
137.
GriffithOW. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem, 257:13704–13712. 1982.
138.
GuevenN, LuffJ, PengC, HosokawaK, BottleSE, LavinMF. Dramatic extension of tumor latency and correction of neurobehavioral phenotype in Atm-mutant mice with a nitroxide antioxidant. Free Radic Biol Med, 41:992–1000. 2006.
139.
GuoJ, PariseRA, JosephE, LanJ, PanSS, JooB, EgorinMJ, WipfP, LazoJS, EisemanJL. Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284)Anticancer Res, 27:3067–3073. 2007.
140.
GuoW, ReiganP, SiegelD, ZirrolliJ, GustafsonD, RossD. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol, 70:1194–1203. 2006.
141.
GuptaA, RosenbergerSF, BowdenGT. Increased ROS levels contribute to elevated transcription factor and MAP kinase activities in malignantly progressed mouse keratinocyte cell lines. Carcinogenesis, 20:2063–2073. 1999.
HayMP, PchalekK, PruijnFB, HicksKO, SiimBG, AndersonRF, ShindeSS, PhillipsV, DennyWA, WilsonWR. Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides:The influence of hydrogen bond donors on extravascular transport and antitumor activity. J Med Chem, 50:6654–6664. 2007.
147.
HibiT, NiiH, NakatsuT, KimuraA, KatoH, HiratakeJ, OdaJ. Crystal structure of gamma-glutamylcysteine synthetase: Insights into the mechanism of catalysis by a key enzyme for glutathione homeostasis. Proc Natl Acad Sci USA, 101:15052–15057. 2004.
148.
HicksKO, PruijnFB, SecombTW, HayMP, HsuR, BrownJM, DennyWA, DewhirstMW, WilsonWR. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst, 98:1118–1128. 2006.
149.
HokeEM, MaylockCA, ShacterE. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radic Biol Med, 39:403–411. 2005.
150.
Holmquist–MengelbierL, FredlundE, LofstedtT, NogueraR, NavarroS, NilssonH, PietrasA, Vallon–ChristerssonJ, BorgA, GradinK, PoellingerL, PahlmanS. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell, 10:413–423. 2006.
151.
HongF, FreemanML, LieblerDC. Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem Res Toxicol, 18:1917–1926. 2005.
152.
HongSH, KimJ, KimJM, LeeSY, ShinDS, SonKH, HanDC, SungYK, KwonBM. Apoptosis induction of 2′-hydroxycinnamaldehyde as a proteasome inhibitor is associated with ER stress and mitochondrial perturbation in cancer cells. Biochem Pharmacol, 74:557–565. 2007.
153.
HosonoT, FukaoT, OgiharaJ, ItoY, ShibaH, SekiT, ArigaT. Diallyl trisulfide suppresses the proliferation and induces apoptosis of human colon cancer cells through oxidative modification of beta-tubulin. J Biol Chem, 280:41487–41493. 2005.
154.
HosonoT, Hosono–FukaoT, InadaK, TanakaR, YamadaH, IitsukaY, SekiT, HasegawaI, ArigaT. Alkenyl group is responsible for the disruption of microtubule network formation in human colon cancer cell line HT-29 cells. Carcinogenesis, 29:1400–1406. 2008.
155.
HuangM, MaynardA, TurpinJA, GrahamL, JaniniGM, CovellDG, RiceWG. Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins. J Med Chem, 41:1371–1381. 1998.
156.
HuangP, FengL, OldhamEA, KeatingMJ, PlunkettW. Superoxide dismutase as a target for the selective killing of cancer cells. Nature, 407:390–395. 2000.
HurneAM, ChaiCL, MoermanK, WaringP. Influx of calcium through a redox-sensitive plasma membrane channel in thymocytes causes early necrotic cell death induced by the epipolythiodioxopiperazine toxins. J Biol Chem, 277:31631–31638. 2002.
159.
HwangJT, GreenbergMM, FuchsT, GatesKS. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: The drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions. Biochemistry, 38:14248–14255. 1999.
160.
IgarashiY, YabutaY, SekineA, FujiiK, HaradaK, OikawaT, SatoM, FurumaiT, OkiT. Directed biosynthesis of fluorinated pseurotin A, synerazol and gliotoxin. J Antibiot (Tokyo), 57:748–754. 2004.
161.
IraniK, XiaY, ZweierJL, SollottSJ, DerCJ, FearonER, SundaresanM, FinkelT, Goldschmidt–ClermontPJ. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science, 275:1649–1652. 1997.
162.
IrelandDJ, KissickHT, BeilharzMW. Alpha-Tocopheryl succinate: Toxicity and lack of anti-tumour activity in immuno-competent mice. Food Chem Toxicol, 46:508–512. 2008.
163.
IshamCR, TibodeauJD, JinW, XuR, TimmMM, BibleKC. Chaetocin: A promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood, 109:2579–2588. 2007.
164.
IshiiT, YasudaK, AkatsukaA, HinoO, HartmanPS, IshiiN. A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res, 65:203–209. 2005.
165.
IyengarBS, DorrRT, RemersWA. Chemical basis for the biological activity of imexon and related cyanoaziridines. J Med Chem, 47:218–223. 2004.
166.
JacobC. A scent of therapy: Pharmacological implications of natural products containing redox-active sulfur atoms. Nat Prod Rep, 23:851–863. 2006.
167.
JellumaN, YangX, StokoeD, EvanGI, DansenTB, Haas–KoganDA. Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res, 4:319–330. 2006.
JeongHW, HanDC, SonKH, HanMY, LimJS, HaJH, LeeCW, KimHM, KimHC, KwonBM. Antitumor effect of the cinnamaldehyde derivative CB403 through the arrest of cell cycle progression in the G2/M phase. Biochem Pharmacol, 65:1343–1350. 2003.
JohnsonKM, ChenX, BoitanoA, SwensonL, OpipariAWJr., GlickGD. Identification and validation of the mitochondrial F1F0-ATPase as the molecular target of the immunomodulatory benzodiazepine Bz-423. Chem Biol, 12:485–496. 2005.
172.
JohnsonKM, ClearyJ, FierkeCA, OpipariAWJr., GlickGD. Mechanistic basis for therapeutic targeting of the mitochondrial F1F0-ATPase. ACS Chem Biol, 1:304–308. 2006.
173.
JuarezJC, BetancourtOJr., Pirie–ShepherdSR, GuanX, PriceML, ShawDE, MazarAP, DonateF. Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res, 12:4974–4982. 2006.
174.
JuarezJC, ManuiaM, BurnettME, BetancourtO, BoivinB, ShawDE, TonksNK, MazarAP, DonateF. Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci USA, 105:7147–7152. 2008.
175.
KachadourianR, LiochevSI, CabelliDE, PatelMN, FridovichI, DayBJ. 2-methoxyestradiol does not inhibit superoxide dismutase. Arch Biochem Biophys, 392:349–353. 2001.
176.
KaelinWGJr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer, 5:689–698. 2005.
KakolyrisS, GiatromanolakiA, KoukourakisM, PowisG, SouglakosJ, SivridisE, GeorgouliasV, GatterKC, HarrisAL. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res, 7:3087–3091. 2001.
179.
KalinowskiDS, RichardsonDR. Future of toxicology—Iron chelators and differing modes of action and toxicity: The changing face of iron chelation therapy. Chem Res Toxicol, 20:715–720. 2007.
KambA, WeeS, LengauerC. Why is cancer drug discovery so difficult?Nat Rev Drug Discov, 6:115–120. 2007.
182.
KantarjianH, O'BrienS, CortesJ, WierdaW, FaderlS, Garcia–ManeroG, IssaJP, EsteyE, KeatingM, FreireichEJ. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer, 113:1933–1952. 2008.
183.
KarS, WangM, YaoW, MichejdaCJ, CarrBI. PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther, 5:1511–1519. 2006.
184.
KarunagaranD, RashmiR, KumarTR. Induction of apoptosis by curcumin and its implications for cancer therapy. Curr Cancer Drug Targets, 5:117–129. 2005.
185.
KashfiK, RigasB. The mechanism of action of nitric oxide-donating aspirin. Biochem Biophys Res Commun, 358:1096–1101. 2007.
186.
KatoM, LiJ, ChuangJL, ChuangDT. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure, 15:992–1004. 2007.
187.
KawiakA, PiosikJ, StasilojcG, Gwizdek-WisniewskaA, MarczakL, StobieckiM, BigdaJ, LojkowskaE. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II. Toxicol Appl Pharmacol, 223:267–276. 2007.
188.
KelnerMJ, AlexanderNM. Methylene blue directly oxidizes glutathione without the intermediate formation of hydrogen peroxide. J Biol Chem, 260:15168–15171. 1985.
189.
KimH, KimEH, EomYW, KimWH, KwonTK, LeeSJ, ChoiKS. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res, 66:1740–1750. 2006.
190.
KimJS, AhnKJ, KimJA, KimHM, LeeJD, LeeJM, KimSJ, ParkJH. Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROS-mediated cell death by 3-BrPA. J Bioenerg Biomembr, 40:607–613. 2008.
191.
KirkpatrickDL, EhrmantrautG, StettnerS, KunkelM, PowisG. Redox active disulfides: The thioredoxin system as a drug target. Oncol Res, 9:351–356. 1997.
192.
KirkpatrickDL, KuperusM, DowdeswellM, PotierN, DonaldLJ, KunkelM, BerggrenM, AnguloM, PowisG. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol, 55:987–994. 1998.
193.
KirshnerJR, HeS, BalasubramanyamV, KeprosJ, YangCY, ZhangM, DuZ, BarsoumJ, BertinJ. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther, 7:2319–2327. 2008.
194.
KirszbergC, RumjanekVM, CapellaMA. Methylene blue is more toxic to erythroleukemic cells than to normal peripheral blood mononuclear cells: A possible use in chemotherapy. Cancer Chemother Pharmacol, 56:659–665. 2005.
195.
KoYH, SmithBL, WangY, PomperMG, RiniDA, TorbensonMS, HullihenJ, PedersenPL. Advanced cancers: Eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun, 324:269–275. 2004.
196.
KohMY, Spivak-KroizmanT, VenturiniS, WelshS, WilliamsRR, KirkpatrickDL, PowisG. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther, 7:90–100. 2008.
197.
KonorevEA, KotamrajuS, ZhaoH, KalivendiS, JosephJ, KalyanaramanB. Paradoxical effects of metalloporphyrins on doxorubicin-induced apoptosis: Scavenging of reactive oxygen species versus induction of heme oxygenase-1. Free Radic Biol Med, 33:988. 2002.
198.
KopninPB, AgapovaLS, KopninBP, ChumakovPM. Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability. Cancer Res, 67:4671–4678. 2007.
199.
KoptyraM, FalinskiR, NowickiMO, StoklosaT, MajsterekI, Nieborowska-SkorskaM, BlasiakJ, SkorskiT. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood, 108:319–327. 2006.
200.
KrishnaMC, DeGraffW, HankovszkyOH, SarCP, KalaiT, JekoJ, RussoA, MitchellJB, HidegK. Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage. J Med Chem, 41:3477–3492. 1998.
201.
KuoPL, ChenCY, HsuYL. Isoobtusilactone A induces cell cycle arrest and apoptosis through reactive oxygen species/apoptosis signal-regulating kinase 1 signaling pathway in human breast cancer cells. Cancer Res, 67:7406–7420. 2007.
202.
KurtogluM, GaoN, ShangJ, MaherJC, LehrmanMA, WangpaichitrM, SavarajN, LaneAN, LampidisTJ. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther, 6:3049–3058. 2007.
203.
KwokBH, KohB, NdubuisiMI, ElofssonM, CrewsCM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol, 8:759–766. 2001.
204.
KwokJC, RichardsonDR. The iron metabolism of neoplastic cells: Alterations that facilitate proliferation?Crit Rev Oncol Hematol, 42:65–78. 2002.
205.
LaiH, SinghNP. Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett, 231:43–48. 2006.
206.
LambertC, LiJ, JonscherK, YangTC, ReiganP, QuintanaM, HarveyJ, FreedBM. Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-kappaB1 DNA binding domain. J Biol Chem, 282:19666–19675. 2007.
207.
LampidisTJ, KurtogluM, MaherJC, LiuH, KrishanA, SheftV, SzymanskiS, FoktI, RudnickiWR, GinalskiK, LesyngB, PriebeW. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing “hypoxic tumor cells”Cancer Chemother Pharmacol, 58:725–734. 2006.
208.
LauA, VilleneuveNF, SunZ, WongPK, ZhangDD. Dual roles of Nrf2 in cancer. Pharmacol Res, 58:262–270. 2008.
209.
LauJP, WeatherdonKL, SkalskiV, HedleyDW. Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. Br J Cancer, 91:1166–1173. 2004.
210.
LaurentA, NiccoC, ChereauC, GoulvestreC, AlexandreJ, AlvesA, LevyE, GoldwasserF, PanisY, SoubraneO, WeillB, BatteuxF. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res, 65:948–956. 2005.
211.
LavecchiaA, ColucciaA, Di GiovanniC, NovellinoE. Cdc25B phosphatase inhibitors in cancer therapy: Latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem, 8:843–856. 2008.
212.
LavecchiaA, CosconatiS, LimongelliV, NovellinoE. Modeling of Cdc25B dual specifity protein phosphatase inhibitors: Docking of ligands and enzymatic inhibition mechanism. ChemMedChem, 1:540–550. 2006.
213.
LeiP, AbdelrahimM, ChoSD, LiuS, ChintharlapalliS, SafeS. 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through activation of c-jun N-terminal kinase. Carcinogenesis, 29:1139–1147. 2008.
214.
LeslieNR. The redox regulation of PI 3-kinase-dependent signaling. Antioxid Redox Signal, 8:1765–1774. 2006.
215.
LeslieNR, BennettD, LindsayYE, StewartH, GrayA, DownesCP. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J, 22:5501–5510. 2003.
216.
LewisA, OughM, LiL, HinkhouseMM, RitchieJM, SpitzDR, CullenJJ. Treatment of pancreatic cancer cells with dicumarol induces cytotoxicity and oxidative stress. Clin Cancer Res, 10:4550–4-558. 2004.
217.
LiPC, LamE, RoosWP, ZdzienickaMZ, KainaB, EfferthT. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res, 68:4347–4351. 2008.
LiuZ, DuZY, HuangZS, LeeKS, GuLQ. Inhibition of thioredoxin reductase by curcumin analogs. Biosci Biotechnol Biochem, 72:2214–2218. 2008.
224.
LixiaG, FeiY, JiajiaJ, JianhuiL. Triethylene tetramine, a novel ligand of G-quadruplex, induces senescence of MCF-7 cells. Biotechnol Lett, 30:47–53. 2008.
225.
LoeweR, ValeroT, KremlingS, PratscherB, KunstfeldR, PehambergerH, PetzelbauerP. Dimethylfumarate impairs melanoma growth and metastasis. Cancer Res, 66:11888–11896. 2006.
Lopez–LazaroM. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 52 Suppl, 1:S103–127. 2008.
228.
LowndesSA, AdamsA, TimmsA, FisherN, SmytheJ, WattSM, JoelS, DonateF, HaywardC, ReichS, MiddletonM, MazarA, HarrisAL. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res, 14:7526–7534. 2008.
229.
LuJ, ChewEH, HolmgrenA. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA, 104:12288–12293. 2007.
230.
LuoM, DelaplaneS, JiangA, ReedA, HeY, FishelM, NylandRL2nd, BorchRF, QiaoX, GeorgiadisMM, KelleyMR. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxid Redox Signal, 10:1853–1867. 2008.
231.
LuoM, KelleyMR. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res, 24:2127–2134. 2004.
232.
MaB, GohBC, TanEH, LamKC, SooR, LeongSS, WangLZ, MoF, ChanAT, ZeeB, MokT. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest New Drugs, 26:169–173. 2008.
233.
MackenzieMJ, SaltmanD, HirteH, LowJ, JohnsonC, PondG, MooreMJ. A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium. Invest New Drugs, 25:553–558. 2007.
234.
MadhusudanS, SmartF, ShrimptonP, ParsonsJL, GardinerL, HoulbrookS, TalbotDC, HammondsT, FreemontPA, SternbergMJ, DianovGL, HicksonID. Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res, 33:4711–4724. 2005.
235.
MaedaH, HoriS, OhizumiH, SegawaT, KakehiY, OgawaO, KakizukaA. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ, 11:737–746. 2004.
236.
MagdaD, LecaneP, MillerRA, LeppC, MilesD, MesfinM, BiaglowJE, HoVV, ChawannakulD, NagpalS, KaramanMW, HaciaJG. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res, 65:3837–3845. 2005.
237.
MagdaD, MillerRA. Motexafin gadolinium: A novel redox active drug for cancer therapy. Semin Cancer Biol, 16:466–476. 2006.
238.
MaoX, YuCR, LiWH, LiWX. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res, 18:879–888. 2008.
239.
MarcuL, OlverI. Tirapazamine: from bench to clinical trials. Curr Clin Pharmacol, 1:71–79. 2006.
240.
MartyM, EspieM, LlombartA, MonnierA, RapoportBL, StahalovaV. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol, 17:614–622. 2006.
241.
MarzanoC, GandinV, FoldaA, ScutariG, BindoliA, RigobelloMP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med, 42:872–881. 2007.
242.
MaschekG, SavarajN, PriebeW, BraunschweigerP, HamiltonK, TidmarshGF, De YoungLR, LampidisTJ. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res, 64:31–34. 2004.
243.
MathupalaSP, KoYH, PedersenPL. Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene, 25:4777–4786. 2006.
MaysJR, Weller RoskaRL, SarfarazS, MukhtarH, RajskiSR. Identification, synthesis, and enzymology of non-natural glucosinolate chemopreventive candidates. Chembiochem, 9:729–747. 2008.
246.
MehtaMP, ShapiroWR, PhanSC, GervaisR, CarrieC, ChabotP, PatchellRA, GlantzMJ, RechtL, LangerC, SurRK, RoaWH, MaheMA, FortinA, NiederC, MeyersCA, SmithJA, MillerRA, RenschlerMF. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: Results of a Phase III trial. Int J Radiat Oncol Biol Phys, 73:1069–1076. 2008.
247.
MeuilletEJ, MahadevanD, BerggrenM, CoonA, PowisG. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: A mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys, 429:123–133. 2004.
248.
MeyskensFL.Jr, FarmerP, FruehaufJP. Redox regulation in human melanocytes and melanoma. Pigment Cell Res, 14:148–154. 2001.
249.
MeyskensFL.Jr, FarmerPJ, YangS, Anton–CulverH. New perspectives on melanoma pathogenesis and chemoprevention. Recent Results Cancer Res, 174:191–195. 2007.
250.
MiL, XiaoZ, HoodBL, DakshanamurthyS, WangX, GovindS, ConradsTP, VeenstraTD, ChungFL. Covalent binding to tubulin by isothiocyanates. A mechanism of cell growth arrest and apoptosis. J Biol Chem, 283:22136–22146. 2008.
251.
MichelakisED, WebsterL, MackeyJR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer, 99:989–994. 2008.
252.
MitsushitaJ, LambethJD, KamataT. The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res, 64:3580–3585. 2004.
253.
MooreJC, LaiH, LiJR, RenRL, McDougallJA, SinghNP, ChouCK. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett, 98:83–87. 1995.
254.
MukherjeeA, HuberK, EvansH, LakhaniN, MartinS. A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines. Br J Pharmacol, 151:1167–1175. 2007.
255.
MukherjeeA, MartinSG. The thioredoxin system: A key target in tumour and endothelial cells. Br J Radiol 81 Spec No, 1:S57–68. 2008.
256.
NakaseI, LaiH, SinghNP, SasakiT. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm, 354:28–33. 2008.
257.
NeuzilJ, TomasettiM, ZhaoY, DongLF, BirringerM, WangXF, LowP, WuK, SalvatoreBA, RalphSJ. Vitamin E analogs, a novel group of “mitocans,” as anticancer agents: the importance of being redox-silent. Mol Pharmacol, 71:1185–1199. 2007.
258.
NguyenC, TeoJL, MatsudaA, EguchiM, ChiEY, HendersonWRJr., KahnM. Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. Proc Natl Acad Sci USA, 100:1169–1173. 2003.
259.
NguyenP, AwwadRT, SmartDD, SpitzDR, GiusD. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett, 236:164–174. 2006.
260.
NicolaouKC, SmithAL, YueEW. Chemistry and biology of natural and designed enediynes. Proc Natl Acad Sci USA, 90:5881–5888. 1993.
261.
NolanKA, ZhaoH, FaulderPF, FrenkelAD, TimsonDJ, SiegelD, RossD, BurkeTRJr., StratfordIJ, BryceRA. Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity. J Med Chem, 50:6316–6325. 2007.
262.
NonnL, BerggrenM, PowisG. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res, 1:682–689. 2003.
263.
NowisD, BugajskiM, WiniarskaM, BilJ, SzokalskaA, SalwaP, IssatT, WasH, JozkowiczA, DulakJ, StoklosaT, GolabJ. Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice. BMC Cancer, 8:197. 2008.
264.
NymanES, HynninenPH. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J Photochem Photobiol B, 73:1–28. 2004.
265.
OhS, KimBJ, SinghNP, LaiH, SasakiT. Synthesis and anticancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett, 274:33–39. 2009.
266.
OhSY, SohnYW, ParkJW, ParkHJ, JeonHM, KimTK, LeeJS, JungJE, JinX, ChungYG, ChoiYK, YouS, LeeJB, KimH. Selective cell death of oncogenic Akt-transduced brain cancer cells by etoposide through reactive oxygen species mediated damage. Mol Cancer Ther, 6:2178–2187. 2007.
267.
OkaD, NishimuraK, ShibaM, NakaiY, AraiY, NakayamaM, TakayamaH, InoueH, OkuyamaA, NonomuraN. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int J Cancer, 120:2576–2581. 2007.
268.
OpsenicaI, OpsenicaD, SmithKS, MilhousWK, SolajaBA. Chemical stability of the peroxide bond enables diversified synthesis of potent tetraoxane antimalarials. J Med Chem, 51:2261–2266. 2008.
269.
PalayoorST, MitchellJB, CernaD, DegraffW, John–AryankalayilM, ColemanCN. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer, 123:2430–2437. 2008.
270.
PanJG, MakTW. Metabolic targeting as an anticancer strategy: dawn of a new era?Sci STKE, 2007:pe14. 2007.
271.
PanXQ, HardayJ. Electromicroscopic observations on gliotoxin-induced apoptosis of cancer cells in culture and human cancer xenografts in transplanted SCID mice. In vivo, 21:259–265. 2007.
272.
PapadopoulosKP, GoelS, BeeramM, WongA, DesaiK, HaigentzM, MilianML, ManiS, TolcherA, LalaniAS, SarantopoulosJ. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res, 14:7110–7115. 2008.
273.
PedersenPL. The cancer cell's “power plants” as promising therapeutic targets: An overview. J Bioenerg Biomembr, 39:1–12. 2007.
274.
PelicanoH, FengL, ZhouY, CarewJS, HilemanEO, PlunkettW, KeatingMJ, HuangP. Inhibition of mitochondrial respiration: A novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem, 278:37832–37839. 2003.
PerryBN, GovindarajanB, BhandarkarSS, KnausUG, ValoM, SturkC, CarrilloCO, SohnA, CerimeleF, DumontD, LoskenA, WilliamsJ, BrownLF, TanX, IoffeE, YancopoulosGD, ArbiserJL. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol, 126:2316–2322. 2006.
277.
PhamNA, HedleyDW. Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents. Exp Cell Res, 264:345–352. 2001.
278.
PourpakA, MeyersRO, SamulitisBK, Sherry ChowHH, KeplerCY, RaymondMA, HershE, DorrRT. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anticancer Drugs, 17:1179–1184. 2006.
279.
PowisG, KirkpatrickDL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol, 7:392–397. 2007.
280.
PowisG, WipfP, LynchSM, BirminghamA, KirkpatrickDL. Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Mol Cancer Ther, 5:630–636. 2006.
281.
PowolnyAA, SinghSV. Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer Lett, 269:305–314. 2008.
282.
PrakashC, SharmaR, GleaveM, NeddermanA. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery. Curr Drug Metab, 9:952–964. 2008.
283.
Quintas–CardamaA, VerstovsekS, FreireichE, KantarjianH, ChenYW, ZingaroR. Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. Anticancer Agents Med Chem, 8:904–909. 2008.
284.
RaisB, CominB, PuigjanerJ, BrandesJL, CreppyE, SaboureauD, EnnamanyR, LeeWN, BorosLG, CascanteM. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett, 456:113–118. 1999.
285.
RalphSJ, NeuzilJ. Mitochondria as targets for cancer therapy. Mol Nutr Food Res, 53:9–28. 2009.
286.
RalserM, WamelinkMM, StruysEA, JoppichC, KrobitschS, JakobsC, LehrachH. A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth. Proc Natl Acad Sci USA, 105:17807–17811. 2008.
287.
RamanathanB, JanKY, ChenCH, HourTC, YuHJ, PuYS. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res, 65:8455–8460. 2005.
288.
RamanathanRK, FakihM, ManiS, DeutschM, PerezRP, RitterMA, EisemanJL, IvySP, TrumpDL, BelaniCP, PariseRA, PotterDM, EgorinMJ. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemother Pharmacol, 57:465–474. 2006.
289.
Ramos-MontoyaA, LeeWN, BassilianS, LimS, TrebukhinaRV, KazhynaMV, CiudadCJ, NoeV, CentellesJJ, CascanteM. Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer. Int J Cancer, 119:2733–2741. 2006.
290.
RaoVA, KleinSR, AgamaKK, ToyodaE, AdachiN, PommierY, ShacterEB. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res, 69:948–957. 2009.
291.
ReedGA, SunegaJM, SullivanDK, GrayJC, MayoMS, CrowellJA, HurwitzA. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3′-diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev, 17:2619–2624. 2008.
292.
ReiganP, ColucciMA, SiegelD, ChillouxA, MoodyCJ, RossD. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells. Biochemistry, 46:5941–5950. 2007.
293.
RiceL, PhoenixDA, WainwrightM, WaringJJ. Effect of increasing methylation on the ability of methylene blue to cause diaphorase-catalyzsed oxidation of NADH. Biochem Soc Trans, 26:S319. 1998.
294.
RigasB. Novel agents for cancer prevention based on nitric oxide. Biochem Soc Trans, 35:1364–1368. 2007.
295.
RocheTE, HiromasaY. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. Cell Mol Life Sci, 64:830–849. 2007.
296.
RodriguesMS, ReddyMM, SattlerM. Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications. Antioxid Redox Signal, 10:1813–1848. 2008.
RoyA, GangulyA, BoseDasguptaS, DasBB, PalC, JaisankarP, MajumderHK. Mitochondria-dependent reactive oxygen species-mediated programmed cell death induced by 3,3′-diindolylmethane through inhibition of F0F1-ATP synthase in unicellular protozoan parasite Leishmania donovani. Mol Pharmacol, 74:1292–1307. 2008.
299.
RozenblatS, GrossmanS, BergmanM, GottliebH, CohenY, DovratS. Induction of G2/M arrest and apoptosis by sesquiterpene lactones in human melanoma cell lines. Biochem Pharmacol, 75:369–382. 2008.
300.
RudolphJ. Cdc25 phosphatases: Structure, specificity, and mechanism. Biochemistry, 46:3595–3604. 2007.
SaavedraJE, SrinivasanA, BuzardGS, DaviesKM, WaterhouseDJ, InamiK, WildeTC, CitroML, CuellarM, DeschampsJR, ParrishD, ShamiPJ, FindlayVJ, TownsendDM, TewKD, SinghS, JiaL, JiX, KeeferLK. PABA/NO as an anticancer lead: Analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity. J Med Chem, 49:1157–1164. 2006.
303.
SablinaAA, BudanovAV, IlyinskayaGV, AgapovaLS, KravchenkoJE, ChumakovPM. The antioxidant function of the p53 tumor suppressor. Nat Med, 11:1306–1313. 2005.
304.
SafeS, PapineniS, ChintharlapalliS. Cancer chemotherapy with indole-3-carbinol, bis(3′-indolyl)methane and synthetic analogs. Cancer Lett, 269:326–338. 2008.
305.
SaitohM, NishitohH, FujiiM, TakedaK, TobiumeK, SawadaY, KawabataM, MiyazonoK, IchijoH. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J, 17:2596–2606. 1998.
306.
SamlowskiWE, PetersenR, CuzzocreaS, MacarthurH, BurtonD, McGregorJR, SalveminiD. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med, 9:750–755. 2003.
307.
SannellaAR, CasiniA, GabbianiC, MessoriL, BiliaAR, VincieriFF, MajoriG, SeveriniC. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications. FEBS Lett, 582:844–847. 2008.
308.
SathishaMP, RevankarVK, PaiKS. Synthesis, structure, electrochemistry, and spectral characterization of bis-isatin thiocarbohydrazone metal complexes and their antitumor activity against ehrlich ascites carcinoma in swiss albino mice. Met Based Drugs, 2008:362105. 2008.
309.
SattlerM, VermaS, ShrikhandeG, ByrneCH, PrideYB, WinklerT, GreenfieldEA, SalgiaR, GriffinJD. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem, 275:24273–24278. 2000.
310.
SchaferFQ, BuettnerGR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med, 30:1191–1212. 2001.
311.
SchitoML, GoelA, SongY, InmanJK, FattahRJ, RiceWG, TurpinJA, SherA, AppellaE. In vivo antiviral activity of novel human immunodeficiency virus type 1 nucleocapsid p7 zinc finger inhibitors in a transgenic murine model. AIDS Res Hum Retroviruses, 19:91–101. 2003.
312.
SeowHA, PenkethPG, ShyamK, RockwellS, SartorelliAC. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: An anticancer agent targeting hypoxic cells. Proc Natl Acad Sci USA, 102:9282–9287. 2005.
313.
ShankarS, ChenQ, GanapathyS, SinghKP, SrivastavaRK. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms. Mol Cancer Ther, 7:2328–2338. 2008.
314.
ShankarS, SrivastavaRK. Involvement of Bcl-2 family members, phosphatidylinositol 3′-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol, 30:905–918. 2007.
315.
ShinoharaM, ShangWH, KuboderaM, HaradaS, MitsushitaJ, KatoM, MiyazakiH, SumimotoH, KamataT. Nox1 redox signaling mediates oncogenic Ras-induced disruption of stress fibers and focal adhesions by down-regulating Rho. J Biol Chem, 282:17640–17648. 2007.
316.
SiegelD, GustafsonDL, DehnDL, HanJY, BoonchoongP, BerlinerLJ, RossD. NAD(P)H:quinone oxidoreductase 1: Role as a superoxide scavenger. Mol Pharmacol, 65:1238–1247. 2004.
SimonsAL, AhmadIM, MattsonDM, DornfeldKJ, SpitzDR. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res, 67:3364–3370. 2007.
319.
SinghA, Boldin–AdamskyS, ThimmulappaRK, RathSK, AshushH, CoulterJ, BlackfordA, GoodmanSN, BunzF, WatsonWH, GabrielsonE, FeinsteinE, BiswalS. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res, 68:7975–7984. 2008.
SinghNP, LaiHC. Artemisinin induces apoptosis in human cancer cells. Anticancer Res, 24:2277–2280. 2004.
322.
SivaramakrishnanS, GatesKS. Possible chemical mechanisms underlying the antitumor activity of S-deoxyleinamycin. Bioorg Med Chem Lett, 18:3076–3080. 2008.
323.
SiwakDR, ShishodiaS, AggarwalBB, KurzrockR. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer, 104:879–890. 2005.
324.
SolitDB, OsmanI, PolskyD, PanageasKS, DaudA, GoydosJS, TeitcherJ, WolchokJD, GerminoFJ, KrownSE, CoitD, RosenN, ChapmanPB. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res, 14:8302–8307. 2008.
325.
SpitzDR, SimJE, RidnourLA, GaloforoSS, LeeYJ. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism?Ann NY Acad Sci, 899:349–362. 2000.
326.
StasiR. Gemtuzumab ozogamicin: An anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther, 8:527–540. 2008.
327.
StephensonCM, LevinRD, LisCG. Phase 1 trial of high-dose intravenous vitamin C treatment for patients with cancer. J Am Osteopath Assoc, 107:212–213. 2007.
328.
StoltzmanCA, PetersonCW, BreenKT, MuoioDM, BillinAN, AyerDE. Glucose sensing by MondoA:Mlx complexes: A role for hexokinases and direct regulation of thioredoxin-interacting protein expression. Proc Natl Acad Sci USA, 105:6912–6917. 2008.
329.
StravopodisDJ, MargaritisLH, VoutsinasGE. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr Med Chem, 14:3122–3138. 2007.
330.
SuhYA, ArnoldRS, LassegueB, ShiJ, XuX, SorescuD, ChungAB, GriendlingKK, LambethJD. Cell transformation by the superoxide-generating oxidase Mox1. Nature, 401:79–82. 1999.
331.
SulimanHB, CarrawayMS, AliAS, ReynoldsCM, Welty–WolfKE, PiantadosiCA. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J Clin Invest, 117:3730–3741. 2007.
332.
SullivanR, GrahamCH. Chemosensitization of cancer by nitric oxide. Curr Pharm Des, 14:1113–1123. 2008.
333.
SuyS, MitchellJB, SamuniA, MuellerS, KasidU. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice. Cancer, 103:1302–1313. 2005.
334.
SweeneyCJ, MehrotraS, SadariaMR, KumarS, ShortleNH, RomanY, SheridanC, CampbellRA, MurryDJ, BadveS, NakshatriH. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther, 4:1004–1012. 2005.
335.
SzatrowskiTP, NathanCF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res, 51:794–798. 1991.
336.
TaggSL, FosterPA, LeeseMP, PotterBV, ReedMJ, PurohitA, NewmanSP. 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: A potential treatment for breast and prostate cancer. Br J Cancer, 99:1842–1848. 2008.
337.
TangY, DongY, VennerstromJL. Synthetic peroxides as antimalarials. Med Res Rev, 24:425–448. 2004.
338.
TarumotoT, NagaiT, OhmineK, MiyoshiT, NakamuraM, KondoT, MitsugiK, NakanoS, MuroiK, KomatsuN, OzawaK. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Exp Hematol, 32:375–381. 2004.
339.
TatumJL, KelloffGJ, GilliesRJ, ArbeitJM, BrownJM, ChaoKS, ChapmanJD, EckelmanWC, FylesAW, GiacciaAJ, HillRP, KochCJ, KrishnaMC, KrohnKA, LewisJS, MasonRP, MelilloG, PadhaniAR, PowisG, RajendranJG, RebaR, RobinsonSP, SemenzaGL, SwartzHM, VaupelP, YangD, CroftB, HoffmanJ, LiuG, StoneH, SullivanD. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol, 82:699–757. 2006.
340.
TeohML, SunW, SmithBJ, OberleyLW, CullenJJ. Modulation of reactive oxygen species in pancreatic cancer. Clin Cancer Res, 13:7441–7450. 2007.
341.
ThimmulappaRK, MaiKH, SrisumaS, KenslerTW, YamamotoM, BiswalS. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res, 62:5196–5203. 2002.
342.
ThomasAA, Le HuerouY, De MeeseJ, GunawardanaI, KaplanT, RomoffTT, GonzalesSS, CondroskiK, BoydSA, BallardJ, BernatB, DeWolfW, HanM, LeeP, LemieuxC, PedersenR, PhenegerJ, PochG, SmithD, SullivanF, WeilerS, WrightSK, LinJ, BrandhuberB, VigersG. Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors. Bioorg Med Chem Lett, 18:2206–2210. 2008.
343.
TibodeauJ, BensonL, IshamC, OwenW, BibleK. The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase. Antioxid Redox Signal, 11:1097–1106. 2009.
TownsendDM, FindlayVL, TewKD. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol, 401:287–307. 2005.
346.
TownsendDM, HeL, HutchensS, GarrettTE, PazolesCJ, TewKD. NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance. Cancer Res, 68:2870–2877. 2008.
347.
TownsendDM, TewKD. Pharmacology of a mimetic of glutathione disulfide. Biomed Pharmacother, 63:75–78. 2009.
348.
ToyokuniS, OkamotoK, YodoiJ, HiaiH. Persistent oxidative stress in cancer. FEBS Lett, 358:1–3. 1995.
ValiM, VossenJA, BuijsM, EnglesJM, LiapiE, VenturaVP, KhwajaA, Acha-NgwodoO, ShanmugasundaramG, SyedL, WahlRL, GeschwindJF. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: A biodistribution and survival study. J Pharmacol Exp Ther, 327:32–37. 2008.
355.
VanderlaagK, SamudioI, BurghardtR, BarhoumiR, SafeS. Inhibition of breast cancer cell growth and induction of cell death by 1,1-bis(3′-indolyl)methane (DIM) and 5,5′-dibromoDIM. Cancer Lett, 236:198–212. 2006.
356.
VaqueroEC, EdderkaouiM, PandolSJ, GukovskyI, GukovskayaAS. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem, 279:34643–34654. 2004.
VerraxJ, StockisJ, TisonA, TaperHS, CalderonPB. Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. Biochem Pharmacol, 72:671–680. 2006.
359.
von EschenbachAC. NCI sets goal of eliminating suffering and death due to cancer by 2015. J Natl Med Assoc, 95:637–639. 2003.
360.
WangLH, YangXY, ZhangX, AnP, KimHJ, HuangJ, ClarkeR, OsborneCK, InmanJK, AppellaE, FarrarWL. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell, 10:487–499. 2006.
361.
WangLH, YangXY, ZhangX, MihalicK, FanYX, XiaoW, HowardOM, AppellaE, MaynardAT, FarrarWL. Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat Med, 10:40–47. 2004.
362.
WangXJ, SunZ, VilleneuveNF, ZhangS, ZhaoF, LiY, ChenW, YiX, ZhengW, WondrakGT, WongPK, ZhangDD. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis, 29:1235–1243. 2008.
363.
WangZY, ChenZ. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 111:2505–2515. 2008.
364.
WardmanP. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem, 8:739–761. 2001.
365.
WaringP, SjaardaA, LinQH. Gliotoxin inactivates alcohol dehydrogenase by either covalent modification or free radical damage mediated by redox cycling. Biochem Pharmacol, 49:1195–1201. 1995.
WellsWW, RocquePA, XuDP, MeyerEB, CharamellaLJ, DimitrovNV. Ascorbic acid and cell survival of adriamycin resistant and sensitive MCF-7 breast tumor cells. Free Radic Biol Med, 18:699–708. 1995.
368.
WelshS, WilliamsR, KirkpatrickL, Paine-MurrietaG, PowisG. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther, 3:233–244. 2004.
369.
WelshSJ, BellamyWT, BriehlMM, PowisG. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res, 62:5089–5095. 2002.
370.
WelshSJ, WilliamsRR, BirminghamA, NewmanDJ, KirkpatrickDL, PowisG. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther, 2:235–243. 2003.
371.
WeydertCJ, WaughTA, RitchieJM, IyerKS, SmithJL, LiL, SpitzDR, OberleyLW. Overexpression of manganese or copper-zinc superoxide dismutase inhibits breast cancer growth. Free Radic Biol Med, 41:226–237. 2006.
372.
WhitnallM, HowardJ, PonkaP, RichardsonDR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA, 103:14901–14906. 2006.
373.
WiatrakBJ. Overview of recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg, 11:433–441. 2003.
374.
WilloughbyJASr., SundarSN, CheungM, TinAS, ModianoJ, FirestoneGL. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem, 284:2203–2213. 2009.
375.
WinskiSL, FaigM, BianchetMA, SiegelD, SwannE, FungK, DuncanMW, MoodyCJ, AmzelLM, RossD. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. Biochemistry, 40:15135–15142. 2001.
376.
WissnerA, MansourTS. The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm (Weinheim), 341:465–477. 2008.
377.
WissnerA, OverbeekE, ReichMF, FloydMB, JohnsonBD, MamuyaN, RosfjordEC, DiscafaniC, DavisR, ShiX, RabindranSK, GruberBC, YeF, HallettWA, NilakantanR, ShenR, WangYF, GreenbergerLM, TsouHR. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)J Med Chem, 46:49–63. 2003.
378.
WolchokJD, WilliamsL, PintoJT, FleisherM, KrownSE, HwuWJ, LivingstonPO, ChangC, ChapmanPB. Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res, 13:189–196. 2003.
379.
WondrakGT. NQO1-activated phenothiazinium redox cyclers for the targeted bioreductive induction of cancer cell apoptosis. Free Radic Biol Med, 43:178–190. 2007.
WondrakGT, JacobsonMK, JacobsonEL. Endogenous UVA-photosensitizers: Mediators of skin photodamage and novel targets for skin photoprotection. Photochem Photobiol Sci, 5:215–237. 2006.
382.
WuFY, SunTP. Vitamin K3 induces cell cycle arrest and cell death by inhibiting Cdc25 phosphatase. Eur J Cancer, 35:1388–1393. 1999.
383.
WuY, ZuK, NiJ, YehS, KasiD, JamesNS, ChemlerS, IpC. Cellular and molecular effects of alpha-tocopheryloxybutyrate: Lessons for the design of vitamin E analog for cancer prevention. Anticancer Res, 24:3795–3802. 2004.
384.
XiaoD, PowolnyAA, SinghSV. Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J Biol Chem, 283:30151–30163. 2008.
385.
XuRH, PelicanoH, ZhangH, GilesFJ, KeatingMJ, HuangP. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia, 19:2153–2158. 2005.
386.
XuRH, PelicanoH, ZhouY, CarewJS, FengL, BhallaKN, KeatingMJ, HuangP. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res, 65:613–621. 2005.
387.
XuY, ShaoY, VoorheesJJ, FisherGJ. Oxidative inhibition of receptor-type protein-tyrosine phosphatase kappa by ultraviolet irradiation activates epidermal growth factor receptor in human keratinocytes. J Biol Chem, 281:27389–27397. 2006.
YamauraM, MitsushitaJ, FurutaS, KiniwaY, AshidaA, GotoY, ShangWH, KuboderaM, KatoM, TakataM, SaidaT, KamataT. NADPH oxidase 4 contributes to transformation phenotype of melanoma cells by regulating G2-M cell cycle progression. Cancer Res, 69:2647–2654. 2009.
390.
YancikR. Population aging and cancer: A cross-national concern. Cancer J, 11:437–441. 2005.
391.
YangS, IraniK, HeffronSE, JurnakF, MeyskensFLJr.Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol Cancer Ther, 4:1923–1935. 2005.
392.
YangS, MeyskensFL. Apurinic/apyrimidinic endonuclease/redox effector factor-1(APE/Ref-1): a unique target for the prevention and treatment of human melanoma. Antioxid Redox Signal, 11:639–650. 2009.
393.
YangWS, StockwellBR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol, 15:234–245. 2008.
394.
YoshidaA, TakemuraH, InoueH, MiyashitaT, UedaT. Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway. Cancer Res, 66:5772–5780. 2006.
395.
Zahedi AvvalF, BerndtC, PramanikA, HolmgrenA. Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)Biochem Biophys Res Commun, 379:775–779. 2009.
396.
ZahlerWL, ClelWW. A specific and sensitive assay for disulfides. J Biol Chem, 243:716–719. 1968.
397.
ZhangH, TrachoothamD, LuW, CarewJ, GilesFJ, KeatingMJ, ArlinghausRB, HuangP. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia, 22:1191–1199. 2008.
398.
ZhangJ, YangPL, GrayNS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer, 9:28–39. 2009.
399.
ZhangS, YangJH, GuoCK, CaiPC. Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett, 253:108–114. 2007.
400.
ZhangZM, YangXY, DengSH, XuW, GaoHQ. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice. Chin Med J (Engl), 120:1336–1342. 2007.
401.
ZhaoY, NeuzilJ, WuK. Vitamin E analogues as mitochondria-targeting compounds: From the bench to the bedside?Mol Nutr Food Res, 53:129–139. 2009.
402.
ZhengY, ShiY, TianC, JiangC, JinH, ChenJ, AlmasanA, TangH, ChenQ. Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene, 23:1239–1247. 2004.
